Search

Your search keyword '"Hashemi, Kimberly B."' showing total 13 results
Start Over Author "Hashemi, Kimberly B."
13 results on '"Hashemi, Kimberly B."'

2. Innovation in Dermatomyositis

Author

Hashemi, Kimberly B., Shaw, Katharina S., Castillo, Rochelle, and Vleugels, Ruth Ann

Abstract

Dermatomyositis (DM) is a rare autoimmune disease defined by the presence of characteristic cutaneous findings, an increased cancer risk, and variable extracutaneous pathology involving the muscles, lungs, gastrointestinal tract, heart, and/or joints. Although the pathogenesis of DM remains incompletely understood, the discovery of myositis-specific autoantibodies has been an important step forward in understanding disease heterogeneity in DM and stratifying risk for extracutaneous disease and malignancy. Moreover, the recent elucidation of key immunologic drivers of DM has laid the groundwork for the development of novel, targeted treatments in the DM therapeutic pipeline.

Published
2025
Full Text
View/download PDF

3. 425 Anifrolumab for the treatment of refractory cutaneous lupus erythematosus in patients: interim analysis of real-world outcomes

Author

Oke, Oluwadamilola, primary, Castillo, Rochelle L., additional, Hashemi, Kimberly B., additional, Rajeh, Ahmad, additional, Ortiz-López, Laura I., additional, Santiago-Soltero, Karla M., additional, Shahriari, Neda, additional, LaChance, Avery H., additional, Shaw, Katharina S., additional, and Vleugels, Ruth Ann, additional

Published
2024
Full Text
View/download PDF

6. De novo autoimmune connective tissue disease and mortality in patients treated with anti-programmed death receptor-1 and anti-programmed death-ligand 1 therapy: a population-level cohort study.

Author

Tang, Kimberly, Rajeh, Ahmad, Shaw, Katharina S, Nguyen, Nga, Wan, Guihong, Hashemi, Kimberly B, Castillo, Rochelle L, Kwatra, Shawn G, LeBoeuf, Nicole R, Vleugels, Ruth Ann, and Semenov, Yevgeniy R

Subjects
HEALTH Insurance Portability & Accountability Act, DRUG side effects, LUPUS erythematosus, PROPORTIONAL hazards models, CONNECTIVE tissue diseases, VITILIGO, POLYARTERITIS nodosa
Abstract

This article discusses the association between immune checkpoint inhibitors (ICIs) and the development of de novo autoimmune cutaneous connective tissue disease (AiCTD). The study utilized the TriNetX Diamond Network, which includes electronic medical records of over 213 million patients from the USA and Europe. The results showed that de novo AiCTDs are rare and not associated with worse outcomes compared to other cutaneous immune-related adverse events. The study adds to the limited information on the development of cutaneous connective tissue diseases following ICI therapy. [Extracted from the article]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results